Maria L Escolar MD
Neurodevelopmental Disabilities
Associate Professor, Pediatrics, University of Pittsburgh School of Medicine
Join to View Full Profile
1450 Raleigh RdSuite 100Chapel Hill, NC 27599
Phone+1 919-966-4135
Fax+1 412-647-4486
Dr. Escolar is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Residency, Pediatrics, 1989 - 1993
Escuela Colombiana de MedicinaClass of 1986
Certifications & Licensure
PA State Medical License 2011 - 2024
NC State Medical License 1998 - 2012
NY State Medical License 1993 - 2000
Clinical Trials
- The Natural History of Metachromatic Leukodystrophy Start of enrollment: 2008 Mar 11
- Diffusion Tensor Imaging (DTI) in Infants With Krabbe Disease
- The Natural History of Infantile Globoid Cell Leukodystrophy Start of enrollment: 2009 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- MBOAT7 encephalopathy: Characterizing the neurology and epileptology.Sebastian Ortiz De la Rosa, Valentina Rizzo, Robin-Tobias Jauss, Tobias Bartolomaeus, Maria Escolar
Epilepsia. 2025-03-21 - Infantile Krabbe disease (0-12 months), progression, and recommended endpoints for clinical trials.Melissa R Greco, Mabel A Lopez, Maria L Beltran-Quintero, Ecenur Tuc Bengur, Michele D Poe
Annals of Clinical and Translational Neurology. 2024-12-01 - Developmental delay can precede neurologic regression in early onset metachromatic leukodystrophy.Laura Ann Adang, Samuel Groeschel, Chloe Grzyb, Russell D'Aiello, Francesco Gavazzi
Molecular Genetics and Metabolism. 2024-08-01
Press Mentions
Forge Biologics Reports Positive FBX-101 Clinical Updates for Patients with Krabbe Disease at WORLDSymposiumFebruary 23rd, 2023- Forge Biologics Announces Updated Positive Clinical Data in RESKUE, a Novel Phase 1/2 Gene Therapy Trial for Patients with Krabbe DiseaseOctober 11th, 2022
- Forge Biologics Reports Positive Clinical Data on Brain Development and Motor Function from the RESKUE Novel Phase 1/2 Gene Therapy Trial in Patients with Krabbe Disease at the SSIEM Annual SymposiumAugust 30th, 2022
- Join now to see all
Grant Support
- DTI As A Tool To Identify Infants With Krabbe Disease In Need Of Urgent TreatmentNational Institute Of Neurological Disorders And Stroke2011–2012
- DTI As A Tool To Identify Infants With Krabbe Disease In Need Of Urgent TreatmentNational Institute Of Neurological Disorders And Stroke2008–2011
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
